Yuhan Corporation said it held its 102nd regular shareholders' meeting at its headquarters in Dongjak, Seoul, on the morning of the 20th.
At the shareholders' meeting that day, Yuhan Corporation approved the financial statements, which included last year's dividend amount, changes to parts of the articles of incorporation, and the approval of the director's compensation limit.
Yuhan Corporation reported last year's revenue at 2.08 trillion won based on separate standards, with an operating profit of 70.1 billion won and a net profit of 96.7 billion won. The company decided to conduct a cash dividend of 500 won per common share and 510 won per preferred share. The total amount of dividends is approximately 37.5 billion won.
The articles of incorporation regarding dividends were also partially amended. Instead of paying on the last day of the settlement of account, the board of directors can set a record date. However, if a record date is set, it must be announced two weeks in advance.
Jo Wook-je, CEO of Yuhan Corporation, noted, "Last year, the non-small cell lung cancer treatment drug Lecarea received approval from the U.S. Food and Drug Administration (FDA) as the first domestically produced anticancer drug for first-line combination therapy," adding, "This achievement allowed us to become the first in the domestic pharmaceutical industry to exceed a net sales of 2 trillion won."
He added, "The company will surely exceed the established goals and enhance its value while also increasing the value for shareholders."